Another Winning Trade – Traders Pick
These medical shares tripled hitting a 52 week high of $0.11 cents earlier in the year before consolidating to current levels. These shares are ready to soar again and a BREAKOUT above the $0.06 level is anticipated . Traders should watch for a move to the upside and a sustained advance to signal the next move All serious investors must place these shares on their BUY LIST – REPORT
The Halberd Corp (OTCMKTS:HALB) stock has been gaining strong momentum in recent days and in such a scenario, it might be a wise move for investors to take a closer look at the company. Halberd is listed on the OTC Markets and at this point, it is fully compliant with all the regulations of the exchange.
More importantly, it is necessary to keep in mind that the company holds a number of patents, some of which include treatments for COVID 19 infection and other conditions. On the other hand, it is also important for investors to take a look at some of the latest developments with regards to Halberd in order to get a better idea of things.
Earlier in the week, the company announced that Dr. Mitchell S. Felder, who had been a consultant for Halberd, had been appointed as the Chief Technical Officer.
The appointment had been made after the existing Chief Technical Officer Dr. Patricio Reyes asked for a reduction in his duties for having been weighed down by outside commitments. Reyes is going to be a part of the company going forward and is going to be working as a consultant.
The appointment of Dr. Felder could prove to be a strategically important one for Halberd, considering the fact that he owns patents in the field of radiofrequency development and has also worked on laser emissive energy meant for extracorporeal eradication of the disease.
Last month the company’s radio frequency disease elimination effort got a significant boost. Halberd announced that it was taking the effort forward by getting Dr. William G. Sturrus of Youngstown State University to lead the radio frequency research program. The research is going to be conducted as part of the Disease Elimination multi-organization Task Force run by Halberd.
It is another step in the right direction for the company and one that might be a source of optimism for many of the company’s investors. On the other hand, last month Halberd Corporation also announced that it submitted an application related to International Patent Cooperation Treaty with regards to its “Covid-19 Inflammatory Cytokine Storm Treatment.”
This could be another major breakthrough for Halberd since such patent protection is going cover the product in as many as 150 nations. In addition to that, Halberd will also be able to get protection simultaneously from other nations in the world who are not part of the treaty.
Neither PSN nor its owners, members, officers, directors, partners, consultants, nor anyone involved in the publication of this website, is a registered investment adviser or broker-dealer or associated person with a registered investment adviser or broker-dealer and none of the foregoing make any recommendation that the purchase or sale of securities of any company profiled in the PSN website is suitable or advisable for any person or that an investment or transaction in such securities will be profitable. The information contained in the PSN website is not intended to be, and shall not constitute, an offer to sell nor the solicitation of any offer to buy any security. The information presented in the PSN website is provided for informational purposes only and is not to be treated as advice or a recommendation to make any specific investment. Please consult with an independent investment adviser and qualified investment professional before making an investment decision.